Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report released on Sunday. The brokerage issued a hold rating on the medical research company’s stock.

Other analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research report on Monday, November 11th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a report on Friday, January 3rd. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Price Performance

CTSO stock opened at $1.01 on Friday. The firm has a market cap of $55.23 million, a P/E ratio of -2.81 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $1.59. The stock has a 50-day simple moving average of $0.92 and a 200-day simple moving average of $1.02.

Hedge Funds Weigh In On Cytosorbents

Institutional investors and hedge funds have recently made changes to their positions in the business. Sargent Investment Group LLC raised its holdings in Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 67,181 shares in the last quarter. Atomi Financial Group Inc. bought a new stake in shares of Cytosorbents in the 3rd quarter worth about $51,000. Finally, Geode Capital Management LLC raised its stake in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.